|
Novel Strategies for Precision T-cell Therapies
|
5R01CA198095-03
|
$520,564
|
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
MOTILITY AND INVASION
|
5P01CA100324-16
|
$2,028,990
|
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Einstein-Rockefeller-CUNY Center for AIDS Research
|
5P30AI124414-02
|
$174,258
|
|
GOLDSTEIN, HARRIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
B7x in Cancer: Mechanisms and Therapies
|
1F30CA224931-01
|
$49,524
|
|
JOHN, PETER
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Use of focused ultrasound to increase melanoma immunogenicity and inhibit tumor-induced T cell tolerance
|
1R01CA226861-01
|
$382,013
|
|
MACIAN, FERNANDO
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Paul Calabresi Career Development Award for Clinical Oncology (K12)
|
5K12CA132783-10
|
$508,802
|
|
PEREZ-SOLER, ROMAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Investigating the role of Nol3 in normal and malignant hematopoiesis
|
1F30CA217063-01A1
|
$49,524
|
|
PISZCZATOWSKI, RICHARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Methylthioadenosine Phosphorylase and AdoMet Synthetase in Cancer
|
5R01CA135405-11
|
$290,592
|
|
SCHRAMM, VERN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Dissecting Skp2 functions in pRb and p53 doubly deficient tumorigenesis
|
5R01CA201458-03
|
$382,013
|
|
ZHU, LIANG
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Molecular Biology in Clinical Oncology Workshop
|
5R25CA057732-26
|
$249,978
|
|
SAWYERS, CHARLES
|
AMERICAN ASSOCIATION FOR CANCER RESEARCH
|
|
Enhanced Training and Mentorship of Hematologic Oncologists
|
2R25CA168526-06
|
$306,150
|
|
SUNG, LILLIAN
|
AMERICAN SOCIETY OF HEMATOLOGY
|
|
WalkIT: Neighborhood walkability and moderation of adaptive walking interventions
|
1R01CA198915-01
|
$625,944
|
$156,486
|
ADAMS, MARC
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Rapid Point of Care Detection of HPV-Associated Malignancies
|
5UG3CA211415-02
|
$338,933
|
|
ANDERSON, KAREN
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Effects of Meditative Movement (Qigong/Tai Chi Easy) on Fatigued Breast Cancer Su
|
1R01CA182901-01A1
|
$652,569
|
$215,348
|
LARKEY, LINDA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Effects of Meditative Movement (Qigong/Tai Chi Easy) on Fatigued Breast Cancer Survivors
|
5R01CA182901-04
|
$612,939
|
$202,270
|
LARKEY, LINDA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Arizona Cancer and Evolution Center (ACE)
|
1U54CA217376-01A1
|
$1,906,167
|
|
MALEY, CARLO
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
IDO-Expressing Immunoregulatory Dendritic Cells
|
5R01CA103320-15
|
$307,800
|
|
MUNN, DAVID
|
AUGUSTA UNIVERSITY
|
|
Development of cell-free DNA assays for HCC screening and liquid biopsy
|
5R01CA202769-03
|
$397,877
|
|
SU, YING-HSIU
|
BARUCH S. BLUMBERG INSTITUTE
|
|
Proteogenomic Translational Research Center for Clinical Proteomic
|
5U01CA214116-02
|
$1,372,508
|
|
RODLAND, KARIN
|
BATTELLE PACIFIC NORTHWEST LABORATORIES
|
|
(PQ3) Identifying Novel Pharmacologic Risk factors for Common Non-AIDS Defining Cancers in Individuals with Well-controlled HIV Infection
|
5R01CA206476-03
|
$706,386
|
|
CHIAO, ELIZABETH
|
BAYLOR COLLEGE OF MEDICINE
|
|
MICROSCALED PROTEOGENOMICS FOR CANCER CLINICAL TRIALS
|
5U01CA214125-02
|
$1,413,657
|
|
ELLIS, MATTHEW
|
BAYLOR COLLEGE OF MEDICINE
|
|
THE INITIATION AND REGULATION OF INFLAMMATION IN NEUROBLASTOMA
|
5R01CA116548-13
|
$249,638
|
|
METELITSA, LEONID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Racial Disparity in Bladder Cancer and Identification of Altered Metabolism in African American Compare to European Bladder Cancer
|
5R01CA220297-02
|
$365,246
|
|
PUTLURI, NAGIREDDY
|
BAYLOR COLLEGE OF MEDICINE
|
|
Wnt pathway dynamics in breast cancer metastasis
|
5K22CA207463-02
|
$188,042
|
|
ROARTY, KEVIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
De facto Target of Histone Deacetylase Inhibitors
|
5R21CA215591-02
|
$172,369
|
|
SUN, ZHENG
|
BAYLOR COLLEGE OF MEDICINE
|
|
METHYLATION BIOMARKER DEVELOPMENT FOR NONINVASIVE DETECTION OF COLORECTAL CANCER
|
5R01CA181572-05
|
$319,735
|
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
CD25-mediated feedback control of BCR-signaling and its oncogenic mimics
|
5R01CA213138-02
|
$395,738
|
|
MUSCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Metabolic basis of B cell lineage leukemia relapse
|
5R35CA197628-03
|
$1,035,561
|
|
MUSCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A novel VLP vaccine to prevent EBV infection and EBV - associated malignancies
|
5R21CA205106-02
|
$176,605
|
|
OGEMBO, JAVIER
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
2P30CA033572-35
|
$2,543,187
|
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A Multimedia Self-Management Intervention to Prepare Family Caregivers and Patients for Lung Cancer Surgery
|
1R01CA217841-01A1
|
$717,367
|
|
SUN, VIRGINIA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Molecular Mechanisms of BRCA1-Dependent DNA Damage Response and Tumorogenesis
|
5R01CA132755-11
|
$382,500
|
|
YU, XIAOCHUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Humanized Anti-Renalase Antibodies for Unresectable Melanoma
|
1R43CA224463-01
|
$299,996
|
|
BERKOWITZ, BARRY
|
BESSOR PHARMA, LLC
|
|
SOX9 Mediation of AR and ERG Driven Prostate Cancer
|
5R01CA168393-05
|
$361,050
|
|
BALK, STEVEN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
BRAFV600E and VEGFR2 synergize to trigger papillary thyroid cancer progression
|
5R01CA181183-05
|
$361,050
|
|
NUCERA, CARMELO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Isolation and Assessment of Blood-Circulating Cancer Exosomes with LSS and SERS Lab on a Chip Optical Spectroscopic Instrument
|
1R01CA218382-01A1
|
$668,549
|
|
PERELMAN, LEV
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
(PQ7) In Vivo Cellular Optical Imaging of Esophageal Tumors and Microenvironment
|
5R01CA205431-03
|
$522,325
|
|
PERELMAN, LEV
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Randomized Trial of a Mammography Decision Aid for Women Aged 75 and Older
|
5R01CA181357-05
|
$414,552
|
|
SCHONBERG, MARA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Discussions of Prognosis and Stopping Cancer Screening in Older Adults
|
5R21CA212386-02
|
$189,709
|
|
SCHONBERG, MARA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Exploiting Metabolic Vulnerabilities in the PI3K and Akt Pathway in Cancer for Therapeutic Benefit
|
5R01CA200671-03
|
$395,738
|
|
TOKER, ALEX
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Characterizing the signaling pathways that regulate Skp2 oncogenic function
|
5R01CA200573-03
|
$395,738
|
|
WEI, WENYI
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting the APC/Cdc20 E3 ubiquitin ligase for chemoradiation sensitization
|
5R01CA200651-03
|
$383,385
|
|
WEI, WENYI
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Novel Uses of PI3K-inhibitors for the Treatment of advanced PIK3CA-mutant Breast Cancer
|
1R01CA226776-01
|
$400,313
|
|
WULF, GERBURG
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
2018 Biomedical Engineering Society (BMES) Cellular and Molecular (CMBE) Conference
|
1R13EB025705-01
|
$3,000
|
|
CHAHINE, NADEEN
|
BIOMEDICAL ENGINEERING SOCIETY
|
|
Role of Insulin Receptor Substrates in Kras-driven lung cancer
|
5R01CA211944-02
|
$404,888
|
|
KALAANY, NADA
|
BOSTON CHILDREN'S HOSPITAL
|
|
Cancer Deep Phenotype Extraction from Electronic Medical Records
|
5U24CA184407-06
|
$993,015
|
|
SAVOVA, GUERGANA
|
BOSTON CHILDREN'S HOSPITAL
|
|
Role of c-Cbl in Colon cancer
|
5R01CA175382-05
|
$361,050
|
|
CHITALIA, VIPUL
|
BOSTON MEDICAL CENTER
|
|
TUMOR SPECIFIC DELIVERY OF VERTICILLIN A OVERCOMES EPIGENETIC SILENCING RESPONSIBLE FOR DRUG RESISTANCE
|
1R01CA227433-01
|
$608,862
|
|
GRINSTAFF, MARK
|
BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
|
|
Illuminating Dynamic Receptor Clustering in the Epidermal Growth Factor Receptor
|
5R01CA138509-10
|
$368,325
|
|
REINHARD, BJOERN
|
BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
|
|
Improving Accuracy and Reliability in Cancer Screening Tests
|
1R01CA226805-01
|
$313,533
|
|
NELSON, KERRIE
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
Total relevant funding to Depression Research for this search: $15,328,582
|